"{\"info\":{\"nct_id\":\"NCT00061308\",\"official_title\":\"An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer\",\"criteria\":\"Inclusion Criteria:\\n\\n* Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease.\\n* At least 4 weeks since last surgery or radiation therapy.\\n* Must have had a treatment-free interval of greater than 6 months following response to platinum.\\n* ECOG performance status of 0,1, or 2.\\n\\nExclusion Criteria:\\n\\n* Women of child-bearing potential that do not practice adequate contraception.\\n* Pregnant or lactating.\\n* Received more than one primary chemotherapy regimen.\\n* Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.\\n* Active uncontrolled infection requiring antibiotics.\\n* Concurrent severe medical problems unrelated to the malignancy which would limit full compliance with the study.\\n* Received radiation to more than 10% of bone.\\n* Prior treatment with topotecan or gemcitabine.\\n* Hypersensitivity to camptothecin or nucleoside analogues.\\n* Use of an investigational agent within 30 days.\"},\"atomic_criteria\":[{\"raw_text\":\"Inclusion Criteria:\",\"paraphrased_text\":\"The following are the criteria for inclusion in the study:\"},{\"raw_text\":\"Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease.\",\"paraphrased_text\":\"The participant must have previously undergone one platinum-based chemotherapy regimen for their primary disease.\"},{\"raw_text\":\"Must have had a treatment-free interval of greater than 6 months following response to platinum.\",\"paraphrased_text\":\"The patient must have been off treatment for more than 6 months after responding to platinum therapy.\"},{\"raw_text\":\"Exclusion Criteria:\",\"paraphrased_text\":\"The following are the exclusion criteria for the trial.\"},{\"raw_text\":\"Women of child-bearing potential\",\"paraphrased_text\":\"Participants must be women who are capable of becoming pregnant.\"},{\"raw_text\":\"do not practice adequate contraception\",\"paraphrased_text\":\"Participants must not be using effective birth control methods.\"},{\"raw_text\":\"Pregnant\",\"paraphrased_text\":\"The participant is currently pregnant.\"},{\"raw_text\":\"lactating\",\"paraphrased_text\":\"The participant is currently lactating.\"},{\"raw_text\":\"Received more than one primary chemotherapy regimen.\",\"paraphrased_text\":\"The participant has undergone more than one initial chemotherapy treatment plan.\"},{\"raw_text\":\"Concomitant or previous malignancies\",\"paraphrased_text\":\"The patient must not have any concomitant or previous malignancies.\"},{\"raw_text\":\"adequately treated basal cell or squamous cell skin cancer\",\"paraphrased_text\":\"The patient may have had basal cell or squamous cell skin cancer if it was adequately treated.\"},{\"raw_text\":\"in situ cervical cancer\",\"paraphrased_text\":\"The patient may have had in situ cervical cancer.\"},{\"raw_text\":\"incidental carcinoid\",\"paraphrased_text\":\"The patient may have had an incidental carcinoid.\"},{\"raw_text\":\"other cancer from which the patient has been disease free for 5 years\",\"paraphrased_text\":\"The patient may have had another type of cancer if they have been disease free for 5 years.\"},{\"raw_text\":\"Active uncontrolled infection requiring antibiotics.\",\"paraphrased_text\":\"The participant must have an active infection that is not controlled and requires antibiotic treatment.\"},{\"raw_text\":\"Concurrent severe medical problems unrelated to the malignancy\",\"paraphrased_text\":\"The participant has severe medical issues that are not related to the cancer.\"},{\"raw_text\":\"which would limit full compliance with the study\",\"paraphrased_text\":\"These medical issues would prevent the participant from fully complying with the study requirements.\"},{\"raw_text\":\"Received radiation to more than 10% of bone.\",\"paraphrased_text\":\"The patient has received radiation treatment to more than 10% of their bone.\"},{\"raw_text\":\"Use of an investigational agent within 30 days.\",\"paraphrased_text\":\"The participant must not have used an investigational agent in the past 30 days.\"}],\"leftovers\":[\"* \",\"* \",\"* \",\" that \",\".\",\"* \",\" or \",\".\",\"* \",\"* \",\" with the exception of \",\", \",\", \",\", or \",\".\",\"* \",\"* \",\" \",\".\",\"* \",\"* \"]}"